MELAN-A/MART-1 antigen expression in cutaneous and ocular melanomas

Journal of Immunotherapy

Volumn 20, Issue 6, 1997, Pages 466-469

  Nicotra, Maria Rita ^a   Nisticò, Paola ^b   Mangoni, Antonella ^b   Di Filippo, Franco ^b   Marincola, Francesco Maria ^c   Natali, Pier Giorgio ^b  

^a CNR   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cutaneous melanomas; MART1; Ocular melanomas

Indexed keywords

HLA A2 ANTIGEN; MELANOMA ANTIGEN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; ORBIT CANCER; PRIORITY JOURNAL; SKIN CANCER; TISSUE DISTRIBUTION;

EID: 0030774252     PISSN: 10538550     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002371-199711000-00006     Document Type: Article

References (18)

1. Boon T, Gajewski TF, Coulie PG. From defined tumor antigens to effective immunization? Immunol Today 1995;16:334-6.
2. Wolfel T, Klehmann E, Muller C, Schutt KH, Meyer zum Buschenfelde KH, Knuth A. Lysis of melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 1989;170:797-810.
3. Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997; 18:175-82.
4. Cormier J, Rosenberg SA, Marincola FM. Enhancement of cellular immune reactivity to MAA antigen by immunization with a MART-1/MelanA derived peptide. Cancer J Sci Am 1997;3: 37-44.
5. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-65.
6. Kawakami Y, Eliyahu S, Delgado CH, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-62.
7. Marincola FM, Hijazi Y, Fetch P, et al. Analysis of expression of melanoma associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in situ lesions. J Immunother 1996;19: 192-205.
8. Kawakami Y, Battles JK, Kobayashi T, et al. Production of recombinant MART-1 proteins and specific anti MART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. J Immunol Methods 1997;202: 13-25.
9. Clark WH, Ainsworth A, Bernardino EA, et al. The development biology of primary cutaneous malignant melanoma. Semin Oncol 1975;2:83-103.
10. Breslow A. Tumor thickness, level of invasion and node dissection in stage-I cutaneous melanoma. Ann Surg 1975;182:572-5.
11. Natali PG, Hamby CV, Felding-Habermann B, et al. Clinical significance of alpha(v) beta3 integrin and intracellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res 1997;57:1554-60.
12. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994;180:1-4.
13. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994;180:35-42.
14. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-9.
15. Marincola FM, Shamamian P, Rivoltini L, et al. HLA associations in the anti-tumor response against malignant melanoma. J Immunother 1996;18:242-52.
16. Chen Y-T, Stockert E, Jungbluth A, et al. Serological analysis of melan-A (MART-1), a melanocyte-specific protein homogenously expressed in human melanomas. Proc Natl Acad Sci USA 1996; 93:5915-9.
17. Jäger E, Ringhoffer M, Altmannsberger M, et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997;71:142-7.
18. Nisticò P, Mottolese M, Mammi C, et al. Low frequency of ErbB-2 proto-oncogene overexpression in human leukocyte antingen-A2-positive breast cancer patients. JNCI 1997;4:319-21.